VcMMAE
产品说明书
 |
同义名 : | mc-vc-PAB-MMAE;MC-Val-Cit-PAB-MMAE;MMAE Vc linker, MMAE antibody conjugate;Vedotin |
| CAS号 : | 646502-53-6 | |
| 货号 : | A153774 | |
| 分子式 : | C68H105N11O15 | |
| 纯度 : | 99%+ | |
| 分子量 : | 1316.626 | |
| MDL号 : | MFCD25372036 | |
| 存储条件： |
Pure form Sealed in dry,Room Temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 55 mg/mL(41.77 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 45 mg/mL(34.18 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Vc-MMAE is a derivate of the antimitotic agent MMAE which has been already linked with the linker dipeptide, valine-citrulline (vc). Vc-MMAE can be directly linked to a monoclonal antibody (MAB) which directs it to the cancer cells. The MMAE part acts as the payload of the ADC. The dipeptide valine-citrulline can be cleaved by lysosome. Thereby, the link between the payload and the monoclonal antibody will cleave and the antimitotic agent MMAE can be released into the cells[1]. Through combination with specific monoclonal antibody through specific linker, for example, the ADC cAC10-vcMMAE, the cytotoxicity and selectivity of MMAE was significantly enhanced. Intravenous injection with cAC10-vcMMAE at dose of 1mg/kg induced complete, durable tumor regression in the Karpas 299 ALCL model[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
0.76mL 0.15mL 0.08mL |
3.80mL 0.76mL 0.38mL |
7.60mL 1.52mL 0.76mL |
| 参考文献 |
|---|